Soelberg Sørensen P, Hammer M
Eur J Clin Pharmacol. 1984;26(6):719-22. doi: 10.1007/BF00541931.
Plasma osmolality, sodium and vasopressin were measured in 7 patients before and during long-term treatment with carbamazepine, under resting conditions, and following an oral water load of 20 ml/kg body weight. During carbamazepine treatment, the ability to excrete the oral water load was decreased, the urine/plasma osmolality ratio was higher, and the free water clearance was lower. In two patients, the ability to excrete the oral water load was severely impaired, and the free water clearance remained negative following water loading. Plasma osmolality and sodium concentration were significantly lower during carbamazepine administration, but despite this the plasma vasopressin concentration remained unchanged or was even slightly increased. Four patients showed inappropriately high vasopressin concentrations in relation to the corresponding plasma osmolality when taking carbamazepine. The findings suggest a decrease in plasma osmolality during carbamazepine treatment, which might account for the inappropriate secretion of vasopressin. The latter might cause clinical symptoms of water intoxication, as has previously been reported in a few patients on carbamazepine therapy.
在7名患者长期服用卡马西平之前、服药期间、静息状态下以及口服20ml/kg体重的水负荷后,测量了他们的血浆渗透压、钠和血管加压素。在卡马西平治疗期间,排出口服水负荷的能力下降,尿/血浆渗透压比值升高,自由水清除率降低。在两名患者中,排出口服水负荷的能力严重受损,水负荷后自由水清除率仍为负值。服用卡马西平期间,血浆渗透压和钠浓度显著降低,但尽管如此,血浆血管加压素浓度仍保持不变或甚至略有升高。4名患者在服用卡马西平时,血管加压素浓度相对于相应的血浆渗透压过高。这些发现表明卡马西平治疗期间血浆渗透压降低,这可能是血管加压素分泌不当的原因。正如之前在少数接受卡马西平治疗的患者中所报道的那样,后者可能会导致水中毒的临床症状。